Olema Pharmaceuticals Enters New Headquarters Lease Agreement

On April 27, 2026, Olema Pharmaceuticals, Inc. entered into a lease agreement with KR Oyster Point II, LLC to relocate its corporate headquarters. The new premises comprise approximately 38,176 square feet across two phases in a facility located at Oyster Point. Phase I (25,048 sq. ft.) is expected to be delivered around September 15, 2026, and Phase II (13,128 sq. ft.) around December 1, 2026. The initial lease term is seven years, with total base rent obligations of approximately $12.36 million for Phase I and $6.15 million for Phase II, net of rent abatement. The company intends to complete the relocation by December 2026, coinciding with the expiration of its current office and lab leases in San Francisco. The agreement includes a one-time termination option at the 60th month for a fee of approximately $1.72 million, a five-year extension option, and a right of first offer for additional space. This filing reflects a creation of a direct financial obligation related to the new lease.